Piqray (Alpelisib) Patent Expiration, LOE Window & CMS Spending

Piqray (Alpelisib) by Novartis: FDA Orange Book core substance LOE 2033-04-29, 0 AB generics, $130.8M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN212526 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-04-29
Last Listed Patent or Exclusivity Date2033-04-29
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$130.8M
2024 Medicare Part D Spend$109.8M
2024 Medicaid Spend$21.0M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 27.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.